Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

A neurotoxin that specifically targets Anopheles mosquitoes.

Contreras E, Masuyer G, Qureshi N, Chawla S, Dhillon HS, Lee HL, Chen J, Stenmark P, Gill SS.

Nat Commun. 2019 Jun 28;10(1):2869. doi: 10.1038/s41467-019-10732-w.

2.

Crystal structure of the catalytic domain of the Weissella oryzae botulinum-like toxin.

Košenina S, Masuyer G, Zhang S, Dong M, Stenmark P.

FEBS Lett. 2019 Jun;593(12):1403-1410. doi: 10.1002/1873-3468.13446. Epub 2019 May 31.

PMID:
31111466
3.

Engineered botulinum neurotoxin B with improved binding to human receptors has enhanced efficacy in preclinical models.

Elliott M, Favre-Guilmard C, Liu SM, Maignel J, Masuyer G, Beard M, Boone C, Carré D, Kalinichev M, Lezmi S, Mir I, Nicoleau C, Palan S, Perier C, Raban E, Zhang S, Dong M, Stenmark P, Krupp J.

Sci Adv. 2019 Jan 16;5(1):eaau7196. doi: 10.1126/sciadv.aau7196. eCollection 2019 Jan.

4.

Small-molecule inhibitor of OGG1 suppresses proinflammatory gene expression and inflammation.

Visnes T, Cázares-Körner A, Hao W, Wallner O, Masuyer G, Loseva O, Mortusewicz O, Wiita E, Sarno A, Manoilov A, Astorga-Wells J, Jemth AS, Pan L, Sanjiv K, Karsten S, Gokturk C, Grube M, Homan EJ, Hanna BMF, Paulin CBJ, Pham T, Rasti A, Berglund UW, von Nicolai C, Benitez-Buelga C, Koolmeister T, Ivanic D, Iliev P, Scobie M, Krokan HE, Baranczewski P, Artursson P, Altun M, Jensen AJ, Kalderén C, Ba X, Zubarev RA, Stenmark P, Boldogh I, Helleday T.

Science. 2018 Nov 16;362(6416):834-839. doi: 10.1126/science.aar8048.

5.

Botulinum and Tetanus Neurotoxins.

Dong M, Masuyer G, Stenmark P.

Annu Rev Biochem. 2019 Jun 20;88:811-837. doi: 10.1146/annurev-biochem-013118-111654. Epub 2018 Nov 2.

PMID:
30388027
6.

Crystal Structure of Botulinum Neurotoxin A2 in Complex with the Human Protein Receptor SV2C Reveals Plasticity in Receptor Binding.

Gustafsson R, Zhang S, Masuyer G, Dong M, Stenmark P.

Toxins (Basel). 2018 Apr 12;10(4). pii: E153. doi: 10.3390/toxins10040153.

7.

Structural characterisation of the catalytic domain of botulinum neurotoxin X - high activity and unique substrate specificity.

Masuyer G, Zhang S, Barkho S, Shen Y, Henriksson L, Košenina S, Dong M, Stenmark P.

Sci Rep. 2018 Mar 14;8(1):4518. doi: 10.1038/s41598-018-22842-4.

8.

Identification of a Botulinum Neurotoxin-like Toxin in a Commensal Strain of Enterococcus faecium.

Zhang S, Lebreton F, Mansfield MJ, Miyashita SI, Zhang J, Schwartzman JA, Tao L, Masuyer G, Martínez-Carranza M, Stenmark P, Gilmore MS, Doxey AC, Dong M.

Cell Host Microbe. 2018 Feb 14;23(2):169-176.e6. doi: 10.1016/j.chom.2017.12.018. Epub 2018 Jan 27.

9.

Mechanism of Peptide Binding and Cleavage by the Human Mitochondrial Peptidase Neurolysin.

Teixeira PF, Masuyer G, Pinho CM, Branca RMM, Kmiec B, Wallin C, Wärmländer SKTS, Berntsson RP, Ankarcrona M, Gräslund A, Lehtiö J, Stenmark P, Glaser E.

J Mol Biol. 2018 Feb 2;430(3):348-362. doi: 10.1016/j.jmb.2017.11.011. Epub 2017 Nov 26.

PMID:
29183787
10.

Identification and characterization of a novel botulinum neurotoxin.

Zhang S, Masuyer G, Zhang J, Shen Y, Lundin D, Henriksson L, Miyashita SI, Martínez-Carranza M, Dong M, Stenmark P.

Nat Commun. 2017 Aug 3;8:14130. doi: 10.1038/ncomms14130.

11.

The structure of the tetanus toxin reveals pH-mediated domain dynamics.

Masuyer G, Conrad J, Stenmark P.

EMBO Rep. 2017 Aug;18(8):1306-1317. doi: 10.15252/embr.201744198. Epub 2017 Jun 23.

12.

Glycans Confer Specificity to the Recognition of Ganglioside Receptors by Botulinum Neurotoxin A.

Hamark C, Berntsson RP, Masuyer G, Henriksson LM, Gustafsson R, Stenmark P, Widmalm G.

J Am Chem Soc. 2017 Jan 11;139(1):218-230. doi: 10.1021/jacs.6b09534. Epub 2016 Dec 27.

PMID:
27958736
13.

Crystal structure of a peptidyl-dipeptidase K-26-DCP from Actinomycete in complex with its natural inhibitor.

Masuyer G, Cozier GE, Kramer GJ, Bachmann BO, Acharya KR.

FEBS J. 2016 Dec;283(23):4357-4369. doi: 10.1111/febs.13928. Epub 2016 Nov 6.

14.

NUDT15 Hydrolyzes 6-Thio-DeoxyGTP to Mediate the Anticancer Efficacy of 6-Thioguanine.

Valerie NC, Hagenkort A, Page BD, Masuyer G, Rehling D, Carter M, Bevc L, Herr P, Homan E, Sheppard NG, Stenmark P, Jemth AS, Helleday T.

Cancer Res. 2016 Sep 15;76(18):5501-11. doi: 10.1158/0008-5472.CAN-16-0584. Epub 2016 Aug 16.

15.

Kinetic and structural characterization of amyloid-β peptide hydrolysis by human angiotensin-1-converting enzyme.

Larmuth KM, Masuyer G, Douglas RG, Schwager SL, Acharya KR, Sturrock ED.

FEBS J. 2016 Mar;283(6):1060-76. doi: 10.1111/febs.13647. Epub 2016 Feb 9.

16.

Structural basis of Ac-SDKP hydrolysis by Angiotensin-I converting enzyme.

Masuyer G, Douglas RG, Sturrock ED, Acharya KR.

Sci Rep. 2015 Sep 25;5:13742. doi: 10.1038/srep13742.

17.

Structural analysis of Clostridium botulinum neurotoxin type D as a platform for the development of targeted secretion inhibitors.

Masuyer G, Davies JR, Moore K, Chaddock JA, Ravi Acharya K.

Sci Rep. 2015 Sep 1;5:13397. doi: 10.1038/srep13397.

18.

Structural basis of multivalent galactose-based dendrimer recognition by human galectin-7.

Ramaswamy S, Sleiman MH, Masuyer G, Arbez-Gindre C, Micha-Screttas M, Calogeropoulou T, Steele BR, Acharya KR.

FEBS J. 2015 Jan;282(2):372-87. doi: 10.1111/febs.13140. Epub 2014 Nov 24.

19.

Angiotensin-I converting enzyme (ACE): structure, biological roles, and molecular basis for chloride ion dependence.

Masuyer G, Yates CJ, Sturrock ED, Acharya KR.

Biol Chem. 2014 Oct;395(10):1135-49. doi: 10.1515/hsz-2014-0157. Review.

PMID:
25205727
20.

Interkingdom pharmacology of Angiotensin-I converting enzyme inhibitor phosphonates produced by actinomycetes.

Kramer GJ, Mohd A, Schwager SL, Masuyer G, Acharya KR, Sturrock ED, Bachmann BO.

ACS Med Chem Lett. 2014 Feb 4;5(4):346-51. doi: 10.1021/ml4004588. eCollection 2014 Apr 10.

21.

Molecular and thermodynamic mechanisms of the chloride-dependent human angiotensin-I-converting enzyme (ACE).

Yates CJ, Masuyer G, Schwager SL, Akif M, Sturrock ED, Acharya KR.

J Biol Chem. 2014 Jan 17;289(3):1798-814. doi: 10.1074/jbc.M113.512335. Epub 2013 Dec 2.

22.

Crystal structures of highly specific phosphinic tripeptide enantiomers in complex with the angiotensin-I converting enzyme.

Masuyer G, Akif M, Czarny B, Beau F, Schwager SL, Sturrock ED, Isaac RE, Dive V, Acharya KR.

FEBS J. 2014 Feb;281(3):943-56. doi: 10.1111/febs.12660. Epub 2013 Dec 24.

23.

Absence of cell surface expression of human ACE leads to perinatal death.

Michaud A, Acharya KR, Masuyer G, Quenech'du N, Gribouval O, Morinière V, Gubler MC, Corvol P.

Hum Mol Genet. 2014 Mar 15;23(6):1479-91. doi: 10.1093/hmg/ddt535. Epub 2013 Oct 24.

24.

Engineered botulinum neurotoxins as new therapeutics.

Masuyer G, Chaddock JA, Foster KA, Acharya KR.

Annu Rev Pharmacol Toxicol. 2014;54:27-51. doi: 10.1146/annurev-pharmtox-011613-135935. Epub 2013 Aug 30. Review.

PMID:
24016211
25.

Fragment-based design for the development of N-domain-selective angiotensin-1-converting enzyme inhibitors.

Douglas RG, Sharma RK, Masuyer G, Lubbe L, Zamora I, Acharya KR, Chibale K, Sturrock ED.

Clin Sci (Lond). 2014 Feb;126(4):305-13. doi: 10.1042/CS20130403.

26.

Structural basis of peptide recognition by the angiotensin-1 converting enzyme homologue AnCE from Drosophila melanogaster.

Akif M, Masuyer G, Bingham RJ, Sturrock ED, Isaac RE, Acharya KR.

FEBS J. 2012 Dec;279(24):4525-34. doi: 10.1111/febs.12038. Epub 2012 Nov 22.

27.

Molecular recognition and regulation of human angiotensin-I converting enzyme (ACE) activity by natural inhibitory peptides.

Masuyer G, Schwager SL, Sturrock ED, Isaac RE, Acharya KR.

Sci Rep. 2012;2:717. doi: 10.1038/srep00717. Epub 2012 Oct 9.

28.

Structure based drug design of angiotensin-I converting enzyme inhibitors.

Anthony CS, Masuyer G, Sturrock ED, Acharya KR.

Curr Med Chem. 2012;19(6):845-55. Review.

PMID:
22214449
29.

Engineering botulinum neurotoxin domains for activation by toxin light chain.

Stancombe PR, Masuyer G, Birch-Machin I, Beard M, Foster KA, Chaddock JA, Acharya KR.

FEBS J. 2012 Feb;279(3):515-23. doi: 10.1111/j.1742-4658.2011.08444.x. Epub 2011 Dec 23.

30.

Structures of engineered Clostridium botulinum neurotoxin derivatives.

Masuyer G, Stancombe P, Chaddock JA, Acharya KR.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2011 Dec 1;67(Pt 12):1466-72. doi: 10.1107/S1744309111034671. Epub 2011 Nov 25.

31.

Inhibition mechanism of human galectin-7 by a novel galactose-benzylphosphate inhibitor.

Masuyer G, Jabeen T, Öberg CT, Leffler H, Nilsson UJ, Acharya KR.

FEBS J. 2012 Jan;279(2):193-202. doi: 10.1111/j.1742-4658.2011.08414.x. Epub 2011 Nov 30.

32.

Structural characterization of angiotensin I-converting enzyme in complex with a selenium analogue of captopril.

Akif M, Masuyer G, Schwager SL, Bhuyan BJ, Mugesh G, Isaac RE, Sturrock ED, Acharya KR.

FEBS J. 2011 Oct;278(19):3644-50. doi: 10.1111/j.1742-4658.2011.08276.x. Epub 2011 Sep 8.

33.

Structure and activity of a functional derivative of Clostridium botulinum neurotoxin B.

Masuyer G, Beard M, Cadd VA, Chaddock JA, Acharya KR.

J Struct Biol. 2011 Apr;174(1):52-7. doi: 10.1016/j.jsb.2010.11.010. Epub 2010 Nov 13.

PMID:
21078393
34.

Identification of a novel snake peptide toxin displaying high affinity and antagonist behaviour for the α2-adrenoceptors.

Rouget C, Quinton L, Maïga A, Gales C, Masuyer G, Malosse C, Chamot-Rooke J, Thai R, Mourier G, De Pauw E, Gilles N, Servent D.

Br J Pharmacol. 2010 Nov;161(6):1361-74. doi: 10.1111/j.1476-5381.2010.00966.x.

35.

Isolation and pharmacological characterization of AdTx1, a natural peptide displaying specific insurmountable antagonism of the alpha1A-adrenoceptor.

Quinton L, Girard E, Maiga A, Rekik M, Lluel P, Masuyer G, Larregola M, Marquer C, Ciolek J, Magnin T, Wagner R, Molgó J, Thai R, Fruchart-Gaillard C, Mourier G, Chamot-Rooke J, Ménez A, Palea S, Servent D, Gilles N.

Br J Pharmacol. 2010 Jan 1;159(2):316-25. doi: 10.1111/j.1476-5381.2009.00532.x. Epub 2009 Dec 15.

36.

Crystal structure of a catalytically active, non-toxic endopeptidase derivative of Clostridium botulinum toxin A.

Masuyer G, Thiyagarajan N, James PL, Marks PM, Chaddock JA, Acharya KR.

Biochem Biophys Res Commun. 2009 Mar 27;381(1):50-3. doi: 10.1016/j.bbrc.2009.02.003. Epub 2009 Feb 8.

PMID:
19351593

Supplemental Content

Loading ...
Support Center